JPRN-UMIN000013492
Completed
未知
Quantitative evaluation of ataxia using a three-axis accelerometer - Quantitative evaluation of ataxia using a three-axis accelerometer
Department of Neurology and Rheumatology, Shinshu University School of Medicine0 sites50 target enrollmentMarch 24, 2014
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Spinocerebellar Degeneration Multiple System Atrophy
- Sponsor
- Department of Neurology and Rheumatology, Shinshu University School of Medicine
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients except spinocerebellar degeneration and multiple system atrophy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A Clinical Study to evaluate the effect of two different combinations of BP medication in patients with uncontrolled BPCTRI/2018/08/015555Current Medical Concepts Pvt Ltd93
Not yet recruiting
Not Applicable
A clinical study to compare effectiveness of screening of retinal conditions of an eye by a software in detecting retinal diseases (diseases related to back of your eye) by processing undilated (without dilating the eyes) retinal fundus (interior surface of the eye) photographs.CTRI/2019/04/018420Carl Zeiss India Pvt Ltd
Not yet recruiting
Not Applicable
Clinical Diagnostic Performance Evaluation of a Measles Rapid Test in SenegalMeaslesPaediatricsPACTR202308652843585Institut Pasteur de Dakar850
Active, not recruiting
Phase 1
A study of fitusiran in hemophilia A and B patients without inhibitorsHemophilia A or Hemophilia BMedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2016-001464-11-DKGenzyme Corporation120
Active, not recruiting
Phase 1
A study of fitusiran (ALN-AT3SC) in hemophilia A and B patients without inhibitorsHemophilia A or Hemophilia BMedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2016-001464-11-HUAlnylam Pharmaceuticals, Inc.90